TNB Financial boosted its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 1.9% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 2,842 shares of the medical research company’s stock after buying an additional 52 shares during the period. TNB Financial’s holdings in Thermo Fisher Scientific were worth $496,000 at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in TMO. HighPoint Advisor Group LLC raised its stake in shares of Thermo Fisher Scientific by 4.1% in the fourth quarter. HighPoint Advisor Group LLC now owns 2,028 shares of the medical research company’s stock worth $324,000 after buying an additional 79 shares in the last quarter. Perigon Wealth Management LLC raised its stake in shares of Thermo Fisher Scientific by 21.4% in the fourth quarter. Perigon Wealth Management LLC now owns 30,230 shares of the medical research company’s stock worth $4,842,000 after buying an additional 5,325 shares in the last quarter. Quadrature Capital Ltd acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $4,745,000. Dodge & Cox acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $7,055,000. Finally, Israel Discount Bank of New York GFN acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $264,000. 87.15% of the stock is currently owned by institutional investors.
Thermo Fisher Scientific Inc (NYSE:TMO) traded up 0.87% during midday trading on Friday, reaching $173.23. The company’s stock had a trading volume of 2,202,642 shares. Thermo Fisher Scientific Inc has a 12-month low of $139.07 and a 12-month high of $182.87. The firm has a 50 day moving average price of $176.78 and a 200-day moving average price of $165.46. The company has a market cap of $67.58 billion, a P/E ratio of 30.18 and a beta of 1.06.
Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.27 by $0.03. The company had revenue of $5 billion during the quarter, compared to analyst estimates of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the business posted $2.03 EPS. On average, equities research analysts predict that Thermo Fisher Scientific Inc will post $9.24 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be paid a $0.15 dividend. The ex-dividend date is Thursday, September 14th. This represents a $0.60 dividend on an annualized basis and a yield of 0.35%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.45%.
TRADEMARK VIOLATION WARNING: This news story was published by BNB Daily and is owned by of BNB Daily. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.baseball-news-blog.com/2017/08/14/tnb-financial-boosts-position-in-thermo-fisher-scientific-inc-tmo-updated-updated-updated.html.
A number of brokerages have recently weighed in on TMO. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $197.00 price objective on the stock in a research report on Tuesday, August 1st. BidaskClub lowered Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Bank of America Corporation restated a “buy” rating and set a $210.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Friday, July 21st. Cleveland Research upgraded Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research report on Thursday, July 20th. Finally, Barclays PLC restated an “overweight” rating and set a $200.00 price target (up from $190.00) on shares of Thermo Fisher Scientific in a research report on Monday, July 17th. One equities research analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $188.56.
In related news, insider Daniel P. Shine sold 4,688 shares of the firm’s stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $171.88, for a total value of $805,773.44. Following the completion of the transaction, the insider now owns 29,200 shares in the company, valued at approximately $5,018,896. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Stephen Williamson sold 2,500 shares of the firm’s stock in a transaction on Monday, June 5th. The stock was sold at an average price of $176.26, for a total value of $440,650.00. Following the completion of the transaction, the chief financial officer now owns 37,790 shares of the company’s stock, valued at approximately $6,660,865.40. The disclosure for this sale can be found here. Insiders sold a total of 27,188 shares of company stock valued at $4,702,223 in the last 90 days. 0.49% of the stock is currently owned by company insiders.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.